Țară: Noua Zeelandă
Limbă: engleză
Sursă: Medsafe (Medicines Safety Authority)
Cisatracurium besilate 0.669%{relative} equivalent to cisatracurium 0.5% w/v
AFT Pharmaceuticals Ltd
Cisatracurium besilate 0.669% w/v (equivalent to cisatracurium 0.5% w/v)
5 mg/mL
Solution for injection
Active: Cisatracurium besilate 0.669%{relative} equivalent to cisatracurium 0.5% w/v Excipient: Benzenesulfonic acid Water for injection
Prescription
Yonsung Fine Chemicals Co. Limited
Cisatracurium-AFT is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. It is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.
Package - Contents - Shelf Life: Vial, Type I glass - 30 ml, with grey rubber stopper - 1 dose units - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
2013-05-13
PRODUCT INFORMATION CISATRACURIUM-AFT AFT PHARMACEUTICALS PTY LTD NAME OF THE DRUG Cisatracurium-AFT contains Cisatracurium besylate The chemical name of cisatracurium besylate is (1R,1’R,2R,2’R,)-2,2’-(3,11-dioxo-4,10- dioxatridecamethylene) bis (1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1- veratrylisoquinolinium) dibenzenesulfonate. The molecular formula of cisatracurium besylate is C 65 H 82 N 2 O 18 S 2 and it has a molecular weight of 1243.5. The structural formula is given below: CAS Number: 96946-42-8 DESCRIPTION Cisatracurium besylate is a white to yellowish powder. Cisatracurium-AFT is supplied in two strengths, either 2 mg or 5 mg (as the besylate salt) of cisatracurium besylate per mL. Cisatracurium-AFT also contains Water for Injections and benzenesulfonic acid. Cisatracurium-AFT does not contain any antimicrobial preservative and is intended for single patient use on one occasion only. Discard any residue. PHARMACOLOGY _PHARMACODYNAMICS _ Cisatracurium besylate, a stereoisomer of atracurium, is an intermediate duration, non- depolarising benzylisoquinolinium skeletal muscle relaxant. Cisatracurium besylate binds to cholinergic receptors on the motor end-plate to antagonise the action of acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is readily reversed by anticholinesterase agents such as neostigmine. 1 The ED 95 (dose required to produce 95% depression of the twitch response of the adductor pollicis muscle to stimulation of the ulnar nerve) of cisatracurium besylate is estimated to be 0.05 mg/kg bodyweight during opioid anaesthesia (thiopentone, fentanyl, midazolam). The recommended intubation dose for cisatracurium in adults is 3 x ED 95 , which has a longer clinically effective duration than the recommended intubation dose of atracurium (2 x ED 95 ) (see DOSAGE AND ADMINISTRATION). The ED 95 of cisatracurium besylate in children during halothane anaesthesia is 0.04 mg/kg bodyweight. Cisatracurium besylate undergoes degradation in the body at physio Citiți documentul complet